Kuitunen, H.K.; Rönkä, A.L.K.; Sonkajärvi, E.M.; Isokangas, J.-M.; Pyörälä, M.; Palosaari, K.A.A.; Jokimäki, A.S.; Partanen, A.E.; Littow, H.J.; Vakkala, M.A.;
et al. Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers 2023, 15, 1341.
https://doi.org/10.3390/cancers15041341
AMA Style
Kuitunen HK, Rönkä ALK, Sonkajärvi EM, Isokangas J-M, Pyörälä M, Palosaari KAA, Jokimäki AS, Partanen AE, Littow HJ, Vakkala MA,
et al. Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers. 2023; 15(4):1341.
https://doi.org/10.3390/cancers15041341
Chicago/Turabian Style
Kuitunen, Hanne K., Aino L. K. Rönkä, Eila M. Sonkajärvi, Juha-Matti Isokangas, Marja Pyörälä, Kari A. A. Palosaari, Anna S. Jokimäki, Anu E. Partanen, Harri J. Littow, Merja A. Vakkala,
and et al. 2023. "Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study" Cancers 15, no. 4: 1341.
https://doi.org/10.3390/cancers15041341
APA Style
Kuitunen, H. K., Rönkä, A. L. K., Sonkajärvi, E. M., Isokangas, J. -M., Pyörälä, M., Palosaari, K. A. A., Jokimäki, A. S., Partanen, A. E., Littow, H. J., Vakkala, M. A., Jantunen, E. J., Huttunen, M. E., Marin, K. J., Aromaa-Häyhä, A. M. K., Auvinen, P. K., Selander, T., Puhakka, I. K., & Kuittinen, O. M.
(2023). Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers, 15(4), 1341.
https://doi.org/10.3390/cancers15041341
